Compounds > 2-aminomethyl-1,4-benzodioxane
Page last updated: 2024-12-05

2-aminomethyl-1,4-benzodioxane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-aminomethyl-1,4-benzodioxane: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15053
SCHEMBL ID407540
SCHEMBL ID11484814
MeSH IDM000599751

Synonyms (69)

Synonym
HMS1704K03
BB 0251426
2,3-dihydro-1,4-benzodioxin-2-ylmethanamine
c-(2,3-dihydro-benzo[1,4]dioxin-2-yl)-methylamine
SDCCGMLS-0065918.P001
946f
2,3-dihydro-1,4-benzodioxin-2-methylamine
lp 1
einecs 224-671-6
1,4-benzodioxin-2-methanamine, 2,3-dihydro-
1,4-benzodioxan-2-methylamine
fourneau 946
aminomethylbenzodioxan
brn 0150152
nsc 116045
2,3-dihydro-1,4-benzodioxin-2-methanamine
lp 1 (pharmaceutical)
OPREA1_026835
nsc116045
nsc-116045
4442-59-5
2-aminomethyl-1,4-benzodioxane, 97%
1-(2,3-dihydro-1,4-benzodioxin-2-yl)methanamine
STK500538
AKOS000200095
2,3-dihydro-1,4-benzodioxin-3-ylmethanamine
A7054
(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanamine
(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)amine
2h,3h-benzo[e]1,4-dioxan-2-ylmethylamine
(2,3-dihydro-1,4-benzodioxin-2-yl)methylamine
2-aminomethylbenzodioxan
F1967-0114
2-(aminomethyl)benzodioxan
2-aminomethylbenzodioxane
BP-11133
FT-0603871
FT-0609626
FT-0603870
FS-1497
(2,3-dihydro-1,4-benzodioxin-2-yl)methanamine
AKOS016343768
2,3-dihydro-1,4-benzodioxin-2-ylmethylamine
BBL020222
SCHEMBL407540
2,3-dihydro-benzo[1,4]dioxin-2-ylmethylamine
2-aminomethyl-1,4-benzodioxane
racemic 2,3-dihydro-1,4-benzdioxin-2-ylmethylamine
1,4-benzodioxan-2-ylmethylamine
1-(2,3-dihydro-1,4-benzodioxin-2-yl) methanamine
racemic 2,3-dihydro-1,4-benzodioxin-2-ylmethylamine
2-aminomethylbenzo-1,4-dioxan
2,3-dihydrobenzo[1,4]dioxin-2-ylmethylamine
AB60219
AB60220
J-500558
SCHEMBL11484814
2,3-dihydro-1,4-benzodioxin-2-ylmethanamine #
mfcd00203985
aminomethyl-1,4-benzodioxane
SY250683
mfcd10697675
4-chloro-3-nitrobenzenesulfonicacid,sodiumsalt
AMY21601
SY014251
2-aminomethyl-2,3-dihydro-benzo[1,4]dioxine
DTXSID801305746
CS-0005269
EN300-34206
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.13 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Plasmodium falciparum Malaria
[description not available]		02.110
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.110
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310